Application of mTORC1/2 inhibitors (AZD8055, WYE-125132, MTI-31, and rapamycin) or genetic mTORC-depletion all reduced TF expression, which appeared to be differentially mediated depending on cellular context. Thus, our results have identified TF as a functional biomarker of mTOR. Downregulation of mTOR-TF axis activity likely contributes to the therapeutic mechanism of mTORC1/2- and TF-targeted agents in EGFR-mut advanced NSCLC and GBM.

over 3 years ago

Journal

EGFR (Epidermal growth factor receptor) • mTOR (Mechanistic target of rapamycin kinase) • CD31 (Platelet and endothelial cell adhesion molecule 1)

EGFR mutation • EGFR expression • MTOR mutation • EGFR H1975

sirolimus • AZD8055 • MTI-31 • WYE-125132